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BACKGROUND
Despite improvements in the management of atrial fibrillation, patients with this 
condition remain at increased risk for cardiovascular complications. It is unclear 
whether early rhythm-control therapy can reduce this risk.
METHODS
In this international, investigator-initiated, parallel-group, open, blinded-outcome-
assessment trial, we randomly assigned patients who had early atrial fibrillation 
(diagnosed ≤1 year before enrollment) and cardiovascular conditions to receive either 
early rhythm control or usual care. Early rhythm control included treatment with 
antiarrhythmic drugs or atrial fibrillation ablation after randomization. Usual care 
limited rhythm control to the management of atrial fibrillation–related symptoms. 
The first primary outcome was a composite of death from cardiovascular causes, 
stroke, or hospitalization with worsening of heart failure or acute coronary syn-
drome; the second primary outcome was the number of nights spent in the hospital 
per year. The primary safety outcome was a composite of death, stroke, or serious 
adverse events related to rhythm-control therapy. Secondary outcomes, including 
symptoms and left ventricular function, were also evaluated.
RESULTS
In 135 centers, 2789 patients with early atrial fibrillation (median time since di-
agnosis, 36 days) underwent randomization. The trial was stopped for efficacy at 
the third interim analysis after a median of 5.1 years of follow-up per patient. A 
first-primary-outcome event occurred in 249 of the patients assigned to early rhythm 
control (3.9 per 100 person-years) and in 316 patients assigned to usual care (5.0 per 
100 person-years) (hazard ratio, 0.79; 96% confidence interval, 0.66 to 0.94; P = 0.005). 
The mean (±SD) number of nights spent in the hospital did not differ significantly 
between the groups (5.8±21.9 and 5.1±15.5 days per year, respectively; P = 0.23). The 
percentage of patients with a primary safety outcome event did not differ signifi-
cantly between the groups; serious adverse events related to rhythm-control ther-
apy occurred in 4.9% of the patients assigned to early rhythm control and 1.4% of 
the patients assigned to usual care. Symptoms and left ventricular function at 2 years 
did not differ significantly between the groups.
CONCLUSIONS
Early rhythm-control therapy was associated with a lower risk of cardiovascular 
outcomes than usual care among patients with early atrial fibrillation and cardio-
vascular conditions. (Funded by the German Ministry of Education and Research 
and others; EAST-AFNET 4 ISRCTN number, ISRCTN04708680; ClinicalTrials.gov 
number, NCT01288352; EudraCT number, 2010 - 021258 - 20.)
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Even with current guideline-based management, patients with atrial fibrilla-tion have stroke, acute coronary syndrome, 
heart failure, and cardiovascular death at a rate 
of approximately 5% of patients per year,1-4 and 
35 to 50% of patients with atrial fibrillation who 
receive adequate anticoagulation either receive 
inpatient therapy or die within 5 years.5,6 These 
complications occur even though most atrial fi-
brillation–related ischemic strokes can be pre-
vented with anticoagulation,3,4 and rate control 
often renders patients asymptomatic.7,8 The risk 
of cardiovascular complications is increased dur-
ing the first year after atrial fibrillation is diag-
nosed (a period referred to here as “early atrial 
fibrillation”).9 Furthermore, rhythm-control ther-
apy may be more effective when delivered early.10,11
Previous trials, including one trial involving 
patients with heart failure, have not shown su-
periority of rhythm control with antiarrhythmic 
drugs over rate control in patients with estab-
lished atrial fibrillation.7,8,12,13 Small trials have 
suggested that atrial fibrillation ablation may im-
prove left ventricular function and may reduce the 
risk of adverse outcomes in patients with atrial 
fibrillation and heart failure,2,14 and in one trial 
the antiarrhythmic drug dronedarone, as com-
pared with placebo, reduced the composite out-
come of death and cardiovascular hospitaliza-
tions.6 Some reports have indicated low rates of 
stroke and death associated with rhythm-control 
therapy,5,15 including atrial fibrillation ablation.16-18 
The Early Treatment of Atrial Fibrillation for 
Stroke Prevention Trial (EAST-AFNET 4) therefore 
was designed to test whether a strategy of early 
rhythm-control therapy that includes atrial fi-
brillation ablation would be associated with bet-
ter outcomes in patients with early atrial fibril-
lation than contemporary, evidence-based usual 
care.11
Me thods
Trial Design and Oversight
We conducted an international, investigator-ini-
tiated, parallel-group, randomized, open, blinded-
outcome-assessment trial. The details of the trial 
design have been published previously.19 The trial 
protocol and statistical analysis plan are avail-
able with the full text of this article at NEJM.org. 
The trial was designed and overseen by an execu-
tive committee supported by a steering commit-
tee and was conducted in accordance with the 
Declaration of Helsinki and the International 
Council for Harmonisation Good Clinical Prac-
tice Guidelines. An independent data and safety 
monitoring board guided the trial. All serious 
adverse events were adjudicated by an indepen-
dent end-point review committee, the members 
of which were not aware of the treatment-group 
assignments. The trial was planned by the Atrial 
Fibrillation Network (AFNET) and the European 
Heart Rhythm Association. AFNET was respon-
sible for the conduct of the trial. The protocol was 
approved by the ethics review boards of all the 
institutions involved. Written informed consent 
was provided by all patients who participated in 
the trial.
AFNET conducted the trial while being ad-
vised by the trial committees and working with 
the contract research organization CRI — the 
Clinical Research Institute. The contract research 
organization and the study sites used the Marvin 
electronic case-report form system (XClinical). 
The Institute of Medical Biometry and Epidemi-
ology at the University Medical Center Hamburg–
Eppendorf served as the core statistical unit. The 
funders of the trial did not influence the trial 
design, data collection, analysis, or the decision 
to publish. The first author wrote the first draft 
of the manuscript. All voting members of the 
executive steering committee (see the Supplemen-
tary Appendix, available at NEJM.org) vouch for 
the accuracy and completeness of the data and for 
the fidelity of the trial to the protocol.
Trial Population
We enrolled adults (≥18 years of age) who had 
early atrial fibrillation (defined as atrial fibrilla-
tion diagnosed ≤12 months before enrollment) 
and who were older than 75 years of age, had 
had a previous transient ischemic attack or stroke, 
or met two of the following criteria: age greater 
than 65 years, female sex, heart failure, hyperten-
sion, diabetes mellitus, severe coronary artery dis-
ease, chronic kidney disease (Modification of Diet 
in Renal Disease stage 3 or 4 [glomerular filtra-
tion rate, 15 to 59 ml per minute per 1.73 m2 of 
body-surface area]), and left ventricular hyper-
trophy (diastolic septal wall width, >15 mm).
Trial Intervention
Treatment of cardiovascular conditions, anticoagu-
lation, and rate control were mandated in all pa-
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tients, in accordance with guideline recommen-
dations.20-22 Patients were randomly assigned in 
a 1:1 ratio to receive early rhythm control or usual 
care, with randomization stratified according to 
site and with variable block lengths used for con-
cealment of assignments.
Early rhythm control required antiarrhythmic 
drugs or atrial fibrillation ablation, as well as 
cardioversion of persistent atrial fibrillation, to 
be initiated early after randomization. Local study 
teams chose the type of rhythm-control therapy 
independently to deliver this treatment, using 
protocol guidance based on current guidelines.20-22 
Patients who were randomly assigned to early 
rhythm-control therapy were asked to transmit a 
patient-operated single-lead electrocardiogram 
(ECG) (Vitaphone) twice per week and when symp-
tomatic. All abnormal ECG recordings were 
forwarded to the study site. Documentation of re-
current atrial fibrillation triggered an in-person 
visit from the site team to escalate rhythm-con-
trol therapy as clinically indicated.
Patients who were randomly assigned to usual 
care were initially treated with rate-control ther-
apy without rhythm-control therapy. Rhythm-con-
trol therapy was used only to mitigate uncon-
trolled atrial fibrillation–related symptoms during 
adequate rate-control therapy (i.e., therapy that 
maintained the heart rate within guideline-rec-
ommended targets).
Outcomes and Adverse Events
The first primary outcome was a composite of 
death from cardiovascular causes, stroke (either 
ischemic and hemorrhagic), or hospitalization 
with worsening of heart failure or acute coronary 
syndrome, analyzed in a time-to-event analysis. 
The second primary outcome was the number of 
nights spent in the hospital per year. Secondary 
outcomes reported here include each component 
of the first primary outcome (analyzed in a time-
to-event analysis), rhythm, left ventricular func-
tion, quality of life (assessed with the European 
Quality of Life–5 Dimensions [EQ-5D] visual 
analogue scale and the 12-Item Short-Form Gen-
eral Health Survey [SF-12]), atrial fibrillation–
related symptoms (assessed as the European 
Heart Rhythm Association [EHRA] score), and 
cognitive function (based on the Montreal Cog-
nitive Assessment [MoCA]) at 2 years. All the 
secondary outcomes are listed in Table S5 in the 
Supplementary Appendix.
The primary safety outcome was a composite 
of death from any cause, stroke, or prespecified 
serious adverse events of special interest cap-
turing complications of rhythm-control therapy. 
Source data on all potential serious adverse events 
and adverse events of special interest were cen-
trally adjudicated by the end-point review com-
mittee.
Follow-up
All patients remained in follow-up from ran-
domization until the end of the trial, death, or 
withdrawal from the trial. At baseline, a medical 
history; information on clinical characteristics, 
therapy, and symptom status (EHRA); responses 
on the MoCA, EQ-5D, and SF-12 questionnaires; 
and an ECG and echocardiogram were obtained. 
A blood specimen was obtained from patients 
who consented to participate in a biomarker sub-
study. Every 6 months, trial sites mailed question-
naires to all patients to obtain information on 
hospitalizations and cardiovascular events. Ques-
tionnaires were reviewed at the contract research 
organization, and source documents for all pos-
sible events were requested from the sites. At 
1 and 2 years, an in-person interview, physical 
examination, and ECG were performed. The 
MoCA, EQ-5D, SF-12, and echocardiography were 
repeated at 2 years.
Statistical Analysis
The trial was designed as an event-driven trial. 
The first and second primary outcomes were 
tested independently for differences between the 
treatment groups at an overall two-sided type 1 
error rate of 4% for the first primary outcome 
and 1% for the second primary outcome to reach 
an overall type 1 error rate of 5%. A between-
group difference of 20% in the annual rate of the 
first primary outcome was deemed a clinically 
relevant difference. We calculated that 685 events 
would be needed to show a 20% difference in the 
event rate for the first primary outcome with a 
power of 80%.
Under the assumption of an event rate of 8% 
per year in the control group, a recruitment time 
of 48 months, a minimum follow-up time of 24 
months, and a loss-to-follow-up of 5% of the ob-
servation time, a sample of 2810 patients was cal-
culated to be needed. After a prespecified blinded 
interim analysis of pooled event data that was 
performed after 42 months of recruitment, fol-
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on September 3, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 4
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
low-up time was increased to 30 months and the 
recruitment period to 65 months, resulting in a 
modified sample of 2745 patients without modi-
fying the required number of events. Three un-
blinded interim analyses for early determination 
of significance were conducted by the data and 
safety monitoring board when 25%, 50%, and 
75% of the required events of the first primary 
outcome had occurred.
The analyses of the primary outcomes includ-
ed all patients who underwent randomization and 
at least one follow-up assessment. The analysis 
of the first primary outcome was a comparison 
of end-point review committee–adjudicated events 
between the treatment groups. The analysis fol-
lowed a group-sequential design with three in-
terim analyses with O’Brien–Fleming stopping 
boundaries and two-sided log-rank tests com-
paring early rhythm control with usual care. 
Deaths from noncardiovascular causes were treat-
ed as censored. Additional events at the termina-
tion of the trial were included with the use of the 
inverse normal method.23 As the primary result of 
the trial, the two-sided P value based on Tsiatis, 
Rosner, and Mehta stagewise ordering, accom-
panied by the corresponding median unbiased 
estimate of the hazard ratio and 96% confidence 
interval, is given.24
The second primary outcome was calculated 
as the observed sum of nights in the hospital 
divided by the individual follow-up time (in days; 
in the case of a follow-up time of 0 days, 0.01 
days of follow-up was assumed) and reported as 
annualized rates. The difference between the 
treatment groups was estimated as the arithme-
tic mean and t-based 99% confidence interval. 
For the primary analysis of the second primary 
outcome, a mixed negative binomial regression 
model was used. Explanations of the sensitivity 
analyses and analyses of secondary outcomes 
and further statistical details are provided in the 
Supplementary Appendix.
We used a multiple-imputation procedure with 
60 imputations to replace missing values for con-
tinuous outcomes and covariates defined for ad-
justment. With the exception of the primary analy-
sis, estimates are reported with two-sided 95% 
confidence intervals throughout (see the statistical 
analysis plan in the protocol). These confidence 
intervals have not been adjusted for multiplicity 
and cannot be used to infer treatment effects. All 
analyses were conducted with Stata software, ver-
sion 16.1 (StataCorp), and R software, version 3.6.1 
(R Project for Statistical Computing).
R esult s
Trial Participants
A total of 2789 patients underwent randomiza-
tion across 135 sites in 11 European countries 
between July 28, 2011, and December 30, 2016. 
The primary intention-to-treat population con-
sisted of all 2789 patients — 1395 assigned to 
early rhythm control and 1394 assigned to usual 
care (Fig. 1). Most patients received guideline-
recommended anticoagulation and therapy for 
cardiovascular conditions (Table 1). Patients 
were enrolled a median of 36 days (interquartile 
range, 6 to 112) after the first diagnosis of atrial 
fibrillation. Demographic and clinical character-
istics were generally well balanced between the 
groups, although the use of digitalis glycosides 
and beta-blockers was slightly more common 
(probably because of the group assignment), and 
statin use slightly less common, among the pa-
tients assigned to usual care (Table 1, Fig. 1, and 
Table S3).
Intervention
Almost all patients (1323 [94.8%]) who were ran-
domly assigned to early rhythm control received 
an antiarrhythmic drug or underwent atrial fibril-
lation ablation (Fig. 1), which replicated clinical 
practice patterns.25 Among the 1395 patients, 
216 (15.4%) had a triggered visit to adapt rhythm-
control therapy. At 2 years, 908 of 1395 patients 
(65.1%) were still receiving rhythm-control ther-
apy (Fig. 1).
Usual care consisted of treatment with rate-
control therapy without rhythm-control therapy 
throughout follow-up in the majority of patients 
assigned to this group. Initially, 1335 (95.8%) of 
the 1394 patients in this group had their condi-
tion managed without rhythm-control therapy; at 
2 years, 1191 of the 1394 patients (85.4%) were 
still not receiving rhythm-control therapy (Fig. 1).
Sinus rhythm was found more often in pa-
tients who had been randomly assigned to receive 
early rhythm control (84.9% at 1 year, 82.1% at 2 
years) than in patients assigned to receive usual 
care (65.5% at 1 year, 60.5% at 2 years) (Table 2; 
imputed estimates are provided in Fig. S3). At 
2 years, 1020 of 1159 patients (88.0%) assigned 
to early rhythm control and 1065 of 1171 patients 
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(90.9%) assigned to usual care were still taking 
oral anticoagulants.
Primary Outcomes
The trial was stopped for efficacy at the third 
interim analysis after a median follow-up of 5.1 
years per patient. A first-primary-outcome event 
occurred in 249 patients assigned to receive early 
rhythm control (3.9 per 100 person-years) and in 
316 patients assigned to receive usual care (5.0 per 
100 person-years) (Table 2). When the results were 
adjusted for the group-sequential design of the 
Figure 1. Screening, Randomization, Treatment, and Follow-up.
Most of the patients assigned to early rhythm-control therapy were initially treated with antiarrhythmic drugs, often 
flecainide. After 2 years of follow-up, 908 of the patients (65.1%) who had been randomly assigned to early rhythm-
control therapy were still receiving active rhythm-control therapy (270 patients treated with atrial fibrillation [AF] ab-
lation and 638 treated with antiarrhythmic drugs), and only 203 patients (14.6%) who had been randomly assigned 
to usual care were receiving rhythm-control therapy (97 treated with AF ablation and 106 treated with antiarrhythmic 
drugs). All patients who underwent randomization were included in the primary analysis.
2789 Underwent randomization
at 135 sites in 11 countries
2810 Patients were assessed for eligibility
21 Did not meet inclusion
criteria
1395 Were assigned to early
rhythm control
1394 Were assigned to usual care
1395 Were included in primary analysis 1394 Were included in primary analysis
Rhythm Control Chosen by Site
Total follow-up yr lost: 681/7596 (9.0%)
524 (6.9%) Follow-up yr lost because 
123 Withdrew 
157 (2.1%) Follow-up yr lost because
102 Were lost to follow-up
Total follow-up yr lost: 491/7479 (6.6%)
339 (4.5%) Follow-up yr lost because
83 Withdrew 
152 (2.0%) Follow-up yr lost because
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Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
Characteristic




Age — yr 70.2±8.4 70.4±8.2
Female sex — no. (%) 645 (46.2) 648 (46.5)
Body-mass index† 29.2±5.4 29.3±5.4
Type of atrial fibrillation — no./total no. (%)
First episode 528/1391 (38.0) 520/1394 (37.3)
Paroxysmal 501/1391 (36.0) 493/1394 (35.4)
Persistent 362/1391 (26.0) 381/1394 (27.3)
Sinus rhythm at baseline — no./total no. (%) 762/1389 (54.9) 743/1393 (53.3)
Median days since atrial fibrillation diagnosis (IQR)‡ 36.0 (6.0–114.0) 36.0 (6.0–112.0)
Absence of atrial fibrillation symptoms — no./total no. (%)§ 395/1305 (30.3) 406/1328 (30.6)
Previous cardioversion — no./total no. (%) 546/1364 (40.0) 543/1389 (39.1)
Concomitant cardiovascular conditions
Previous stroke or transient ischemic attack — no. (%) 175 (12.5) 153 (11.0)
At least mild cognitive impairment — no./total no. (%)¶ 582/1326 (43.9) 584/1341 (43.5)
Arterial hypertension — no. (%) 1230 (88.2) 1220 (87.5)
Blood pressure — mm Hg‖
Systolic 136.5±19.4 137.5±19.3
Diastolic 80.9±12.1 81.3±12.0
Stable heart failure — no. (%)** 396 (28.4) 402 (28.8)
CHA2DS2-VASc score†† 3.4±1.3 3.3±1.3
Valvular heart disease — no./total no. (%) 609/1389 (43.8) 642/1391 (46.2)
Chronic kidney disease of MDRD stage 3 or 4 — no. (%)‡‡ 172 (12.3) 179 (12.8)
Medication at discharge — no./total no. (%)§§
Oral anticoagulation with NOAC or VKA 1267/1389 (91.2) 1250/1393 (89.7)
Digoxin or digitoxin 46/1389 (3.3) 85/1393 (6.1)
Beta-blocker 1058/1389 (76.2) 1191/1393 (85.5)
ACE inhibitors or angiotensin II receptor blocker 953/1389 (68.6) 979/1393 (70.3)
Mineralocorticoid-receptor antagonist 90/1389 (6.5) 92/1393 (6.6)
Diuretic 559/1389 (40.2) 561/1393 (40.3)
Statin 628/1389 (45.2) 568/1393 (40.8)
Platelet inhibitor 229/1389 (16.5) 226/1393 (16.2)
*  Plus–minus values are means ±SD. Definitions of clinical measures are provided in Table S1. ACE denotes angiotensin-converting en-
zyme, IQR interquartile range, NOAC non–vitamin K antagonist oral anticoagulant, and VKA vitamin K antagonist.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters. Data were missing for 7 patients assigned 
to early rhythm control and for 6 patients assigned to usual care.
‡  Data on median days since atrial fibrillation diagnosis were missing for 2 patients assigned to early rhythm control and for 1 patient as-
signed to usual care.
§  The absence of symptoms was defined as a European Heart Rhythm Association (EHRA) score of I. The EHRA score categorizes symp-
toms related to atrial fibrillation into four classes from I (asymptomatic) to IV (severe symptoms at rest).
¶  At least mild cognitive impairment was defined as a Montreal Cognitive Assessment (MoCA) score of less than 26. The MoCA score pro-
vides an overall assessment of cognitive function. Scores range from 0 to 30, with lower scores indicating worse cognitive function.
‖  Data on blood pressure were missing for 9 patients assigned to early rhythm control and 4 patients assigned to usual care.
**  Stable heart failure was defined as New York Heart Association stage II or a left ventricular ejection fraction of less than 50%.
††  CHA2DS2-VASc scores (an assessment of the risk of stroke among patients with atrial fibrillation) range from 0 to 9, with higher scores 
indicating a higher risk of stroke.
‡‡  A Modification of Diet in Renal Disease (MDRD) stage of 3 or 4 indicates a glomerular filtration rate of 15 to 59 ml per minute per 1.73 m2 of 
body-surface area.
§§  Because of the high proportion of patients with atrial fibrillation that was first diagnosed at enrollment, important therapies were initiated 
between enrollment and discharge from the baseline visit. Therefore, medication at discharge from the baseline visit is shown.
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trial, a first-primary-outcome event was found 
to have occurred less often in patients assigned 
to early rhythm control than in patients as-
signed to usual care (hazard ratio, 0.79; 96% 
confidence interval [CI], 0.66 to 0.94; P = 0.005) 
(Fig. 2). The effects of early rhythm control on 
individual components of the first primary out-
come were consistent with the overall result 
(Table 2 and Fig. S4). The effect of early rhythm 
control on the first primary outcome remained 
stable after adjustment for relevant covariates 
(hazard ratio, 0.78; 95% CI, 0.66 to 0.92; P = 0.004) 
(Fig. S1), and the effect was consistent across 
subgroups (Fig. S5). There was no significant 
difference in the mean (±SD) number of nights 
spent in the hospital between the treatment 
groups (early rhythm control, 5.8±21.9 days per 
year; usual care, 5.1±15.5 days per year; P = 0.23) 
(Table 2).
The numbers of patients with a primary-safety-
Table 2. Efficacy Outcomes.*
Outcome Early Rhythm Control Usual Care Treatment Effect
First primary outcome — events/person-yr (incidence/ 
100 person-yr)
249/6399 (3.9) 316/6332 (5.0) 0.79 (0.66 to 0.94)†
Components of first primary outcome — events/person-yr 
(incidence/100 person-yr)
Death from cardiovascular causes 67/6915 (1.0) 94/6988 (1.3) 0.72 (0.52 to 0.98)‡
Stroke 40/6813 (0.6) 62/6856 (0.9) 0.65 (0.44 to 0.97)‡
Hospitalization with worsening of heart failure 139/6620 (2.1) 169/6558 (2.6) 0.81 (0.65 to 1.02)‡
Hospitalization with acute coronary syndrome 53/6762 (0.8) 65/6816 (1.0) 0.83 (0.58 to 1.19)‡
Second primary outcome — nights spent in hospital/yr 5.8±21.9 5.1±15.5 1.08 (0.92 to 1.28)§
Key secondary outcomes at 2 yr
Change in left ventricular ejection fraction — % 1.5±9.8 0.8±9.8 0.23 (−0.46 to −0.91)¶
Change in EQ-5D score‖ −1.0±21.4 −2.7±22.3 1.07 (−0.68 to 2.82)¶
Change in SF-12 Mental Score** 0.7±10.6 1.6±10.1 −1.20 (−2.04 to −0.37)¶
Change in SF-12 Physical Score** 0.3±8.5 0.1±8.2 0.33 (−0.39 to 1.06)¶
Change in MoCA score 0.1±3.3 0.1±3.2 −0.14 (−0.39 to 0.12)¶
Sinus rhythm — no. of patients with feature/total no. (%) 921/1122 (82.1) 687/1135 (60.5) 3.13 (2.55 to 3.84)††
Asymptomatic — no. of patients with feature/total no. (%)‡‡ 861/1159 (74.3) 850/1171 (72.6) 1.14 (0.93 to 1.40)††
*  Plus–minus values are means ±SD. Data in columns 2 and 3 are observed data, and data in column 4 are model-based effect estimates. 
There were no significant differences in the key secondary outcomes between the treatment groups, with two exceptions: more patients 
assigned to early rhythm control were in sinus rhythm at 2 years, and a slightly greater improvement in the 12-Item Short-Form Health 
Survey (SF-12) mental score at 2 years was found in the group assigned to usual care. All 95% confidence intervals for secondary end 
points were not adjusted for multiplicity and should not be used to infer definitive treatment effects. The results for additional secondary 
outcomes are provided in the Supplementary Appendix.
†  The treatment effect is expressed as the median unbiased estimate of the hazard ratio and 96% confidence interval, which were calculated 
on the basis of Tsiatis, Rosner, and Mehta stagewise ordering that adjusts for the group-sequential design.24 P = 0.005 for the between-
group comparison.
‡  The treatment effect is expressed as the hazard ratio and 95% confidence interval, which were calculated with a Cox regression with treat-
ment group as the fixed factor and site as the shared frailty term.
§  The treatment effect is expressed as the incidence rate ratio and 99% confidence interval, which were calculated with a mixed negative bi-
nomial model with treatment group as the fixed factor, the log of follow-up time as the offset, and site as a random effect. P = 0.23 for the 
between-group comparison.
¶  The treatment effect is expressed as the adjusted mean difference and 95% confidence interval, which were calculated with a mixed linear 
model with the corresponding baseline measurement and treatment group as the fixed effects and site as a random effect, analyzed after 
multiple imputation of missing values in survivors.
‖  The European Quality of Life–5 Dimensions (EQ-5D) assesses state of health on visual analogue scale from 0 (very bad health) to 100 
(perfect health); values were defined as 0 for nonsurvivors.
**  Scores on the SF-12 range from 0 to 100, with lower scores indicating worse functioning.
††  The treatment effect is expressed as the odds ratio and 95% confidence interval, which were calculated with a mixed logistic regression 
including treatment group and the corresponding baseline assessment as fixed factors and site as a random effect, analyzed after multiple 
imputation of missing values in survivors.
‡‡  The absence of symptoms was defined as an EHRA score of I.
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outcome event did not differ significantly be-
tween the treatment groups (early rhythm con-
trol, 231 patients; usual care, 223 patients) (Table 3 
and Table S4). Mortality was similar in the two 
treatment groups, and stroke occurred less fre-
quently among patients assigned to early rhythm 
control than among those assigned to usual care. 
Serious adverse events related to rhythm-control 
therapy were more common in the group assigned 
to early rhythm control but were infrequent; dur-
ing the 5-year follow-up period, such events oc-
curred in 68 patients (4.9%) assigned to early 
rhythm control and 19 patients (1.4%) assigned 
to usual care (Table 3 and Table S4).
Secondary Outcomes
Left ventricular function and cognitive function 
were stable at 2 years, with no evidence of sig-
nificant differences between the treatment 
groups (Table 2). Most patients in both groups 
were free from atrial fibrillation–related symp-
toms at 2 years, and the change from baseline in 
atrial fibrillation–related symptoms (EHRA score) 
and quality of life (EQ-5D score) did not differ 
significantly between the groups (Table 2).
Discussion
In this multicenter randomized trial, a strategy of 
initiating rhythm-control therapy in all patients 
with early atrial fibrillation and concomitant 
cardiovascular conditions was associated with a 
lower risk of death from cardiovascular causes, 
stroke, or hospitalization for heart failure or acute 
coronary syndrome than usual care over a follow-
up time of more than 5 years (absolute difference 
in risk, 1.1 events per 100 person-years).
Early rhythm control did not affect the num-
ber of nights spent in the hospital. The absence 
of an appreciable difference in hospital nights is 
reassuring in view of the excess hospitalizations 
associated with rhythm-control therapy reported 
in two previous large trials.8,13
Most patients (>70%) were asymptomatic at 
1 and 2 years in both treatment groups, and the 
magnitude of change in left ventricular function 
did not differ between the groups at 2 years, 
which indicates that both rate control and rhythm 
control can control symptoms and maintain car-
diac function in patients with early atrial fibril-
lation. The effects of an early rhythm-control 
strategy on the primary outcome appeared to be 
generally consistent across predefined subgroups, 
including asymptomatic patients, patients with 
obesity, and patients with or without heart failure.
Previous studies comparing rate-control and 
rhythm-control strategies did not show better 
outcomes with rhythm control than with rate 
control.7,8,12,13 In contrast to those trials, our trial 
included atrial fibrillation ablation, a powerful 
rhythm-control therapy5,26 that works synergisti-
cally with antiarrhythmic drugs.27,28 It is conceiv-
able that atrial fibrillation ablation contributed 
to the superiority of early rhythm control in our 
trial. Also, unlike patients in previous tri-
als,7,8,12,13 most patients in both treatment groups 
in our trial continued to receive anticoagulation, 
rate control, and treatment of concomitant cardio-
vascular conditions, maintaining their protective 
effects.
Whereas previous trials have evaluated rhythm 
control in patients with established, long-stand-
ing atrial fibrillation,7,8,12,13 we enrolled patients 
with early atrial fibrillation and initiated rhythm-
control therapy shortly after the diagnosis of 
atrial fibrillation. Furthermore, 54% of the pa-
tients were in sinus rhythm at enrollment. In one 
large previous trial, rhythm-control therapy with 
Figure 2. Aalen–Johansen Cumulative-Incidence Curves for the First  
Primary Outcome.
The first primary outcome was a composite of death from cardiovascular 
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the antiarrhythmic drug dronedarone was found 
to reduce the risk of death or hospitalization for 
cardiovascular causes6 and, in a post hoc analy-
sis, was found to reduce the risk of stroke.29 The 
majority of patients in that trial had had atrial 
fibrillation for less than 1 year (68% of the 2859 
patients in whom the duration of atrial fibrilla-
tion was known), and 75% of the patients were 
in sinus rhythm at enrollment. Almost no pa-
tients were in sinus rhythm at the time of enroll-
ment in another trial, in which harm was shown 
when dronedarone was tested in patients with 
chronic atrial fibrillation (most of whom had 
had atrial fibrillation for >2 years at enrollment).30 
Our results, together with other published evi-
dence, suggest that the early initiation of rhythm-
control therapy probably contributed to the clini-
cal superiority of this strategy.
Early rhythm-control therapy used in the 
present trial included all major antiarrhythmic 
drugs and atrial fibrillation ablation, and there 
were no significant differences between the treat-
ment groups with respect to the primary safety 
outcome. Early rhythm control was associated 
with more adverse events related to rhythm-con-
trol therapy than was usual care, but such events 
were uncommon, similar to the results of other 
recent trials comparing rhythm-control therapies 
in patients with atrial fibrillation.5,26 Early initia-
tion of rhythm-control therapy, guidance on the 
Table 3. Safety Outcomes.*
Outcome





Primary composite safety outcome 231 (16.6) 223 (16.0)
Stroke 40 (2.9) 62 (4.4)
Death 138 (9.9) 164 (11.8)
Serious adverse event of special interest related to rhythm-control therapy 68 (4.9) 19 (1.4)
Serious adverse event related to antiarrhythmic drug therapy
Nonfatal cardiac arrest 1 (0.1) 1 (0.1)
Toxic effects of atrial fibrillation–related drug therapy 10 (0.7) 3 (0.2)
Drug-induced bradycardia 14 (1.0) 5 (0.4)
Atrioventricular block 2 (0.1) 0
Torsades de pointes tachycardia 1 (0.1) 0
Serious adverse event related to atrial fibrillation ablation
Pericardial tamponade 3 (0.2) 0
Major bleeding related to atrial fibrillation ablation 6 (0.4) 0
Nonmajor bleeding related to atrial fibrillation ablation 1 (0.1) 2 (0.1)
Other serious adverse event of special interest related to rhythm-control therapy
Blood pressure–related event† 1 (0.1) 0
Hospitalization for atrial fibrillation 11 (0.8) 3 (0.2)
Other cardiovascular event 5 (0.4) 1 (0.1)
Other event 1 (0.1) 3 (0.2)
Syncope 4 (0.3) 1 (0.1)
Hospitalization for worsening of heart failure with decompensated heart failure 3 (0.2) 0
Implantation of a pacemaker, defibrillator, cardiac resynchronization device, or any 
other cardiac device
8 (0.6) 4 (0.3)
*  Patients could have had more than one event, and therefore the total sum of events is higher than the number of patients with events. For 
dichotomous outcomes, mixed logistic-regression models with a random effect for site were used for comparison of random groups. Stroke 
was significantly less frequent (P = 0.03) and serious adverse events of special interest significantly more frequent (P<0.001) in the group as-
signed to early rhythm control; the other safety outcomes did not differ significantly between the groups.
†  Blood pressure–related events included hypotension and hypertension (excluding syncope).
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on September 3, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 10
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
safe use of antiarrhythmic drugs,20-22 and the 
availability of atrial fibrillation ablation may have 
contributed to the low incidence of adverse events 
associated with rhythm-control therapy, as com-
pared with previous trials.7,8,12,13
Some limitations of our trial should be noted. 
We compared two treatment strategies that ne-
cessitated an open trial design. Blinded, central 
assessment of primary outcomes was used to 
minimize bias. The trial was not primarily de-
signed to assess the safety and effectiveness of 
specific components of early rhythm control. We 
enrolled only patients with early atrial fibrilla-
tion, and thus the results may not be generaliz-
able to patients in whom rhythm-control therapy 
that includes atrial fibrillation ablation is initi-
ated later. Further analysis is needed of the costs 
of early rhythm control. All enrolled patients were 
deemed eligible for either rate-control or rhythm-
control therapy, which probably excluded the most 
symptomatic patients. We did not collect detailed 
information on recurrent atrial fibrillation in 
both groups, and therefore our data on percent-
ages of patients with sinus rhythm are not com-
parable to data on recurrent atrial fibrillation 
from other rhythm-control trials.5,11,26
Early initiation of rhythm-control therapy was 
associated with less frequent cardiovascular events 
than usual care in patients with early atrial fi-
brillation and cardiovascular conditions without 
affecting the number of nights spent in the hos-
pital. As expected, the early rhythm-control strat-
egy was associated with more adverse events re-
lated to rhythm-control therapy, but the incidence 
of the overall safety outcome events was similar 
in the two groups. These results are relevant to 
decisions regarding rhythm-control therapy in pa-
tients with early atrial fibrillation.
Supported by a grant from the German Ministry of Educa-
tion and Research (01 GI 0204), the German Center for Car-
diovascular Research (DZHK), the Atrial Fibrillation Network 
(AFNET), the European Heart Rhythm Association, St. Jude 
Medical–Abbott, Sanofi, the German Heart Foundation, the 
European Union (grant agreement 633196 [CATCH ME], to 
Dr. Kirchhof and AFNET and grant agreement EU IMI 116074 
[BigData@Heart], to Dr. Kirchhof), the British Heart Foun-
dation (FS/13/43/30324, PG/17/30/32961, PG/20/22/35093, and 
AA/18/2/34218, to Dr. Kirchhof), and the Leducq Foundation 
(to Dr. Kirchhof).
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
We thank all the patients who agreed to participate in the 
trial, and especially those who stayed in the trial for many years; 
all local study teams; the dedicated staff at AFNET and CRI — 
the Clinical Research Institute; and all committee members (see 
the Supplementary Appendix).
Appendix
The authors’ full names and academic degrees are as follows: Paulus Kirchhof, M.D., A. John Camm, M.D., Andreas Goette, M.D., Axel 
Brandes, M.D., Lars Eckardt, M.D., Arif Elvan, M.D., Thomas Fetsch, M.D., Isabelle C. van Gelder, M.D., Doreen Haase, Ph.D., Lau-
rent M. Haegeli, M.D., Frank Hamann, M.D., Hein Heidbüchel, M.D., Ph.D., Gerhard Hindricks, M.D., Josef Kautzner, M.D., Karl-Heinz 
Kuck, M.D., Lluis Mont, M.D., G. Andre Ng, M.B., Ch.B., Ph.D., Jerzy Rekosz, M.D., Norbert Schoen, M.D., Ulrich Schotten, M.D., 
Ph.D., Anna Suling, Ph.D., Jens Taggeselle, M.D., Sakis Themistoclakis, M.D., Eik Vettorazzi, M.Sc., Panos Vardas, M.D., Ph.D., Karl 
Wegscheider, Ph.D., Stephan Willems, M.D., Harry J.G.M. Crijns, M.D., Ph.D., and Günter Breithardt, M.D.
The authors’ affiliations are as follows: the Department of Cardiology, University Heart and Vascular Center (P.K.), and Institute of 
Medical Biometry and Epidemiology (A.S., E.V., K.W.), University Medical Center Hamburg–Eppendorf, LANS Cardio (K.-H.K.), and 
the Department of Cardiology, Asklepios Klinik St. Georg (S.W.), Hamburg, Atrial Fibrillation Network (AFNET) (P.K., A.G., L.E., T.F., 
D.H., K.-H.K., N.S., U.S., J.T., K.W., S.W., G.B.) and the Department of Cardiology II (Electrophysiology), University Hospital Münster 
(L.E., G.B.), Münster, the German Center of Cardiovascular Research, Partner Site Hamburg/Lübeck/Kiel (P.K., K.W., S.W.), St. Vincenz 
Hospital, Paderborn (A.G.), the Working Group of Molecular Electrophysiology, University Hospital Magdeburg, Magdeburg (A.G.), the 
Clinical Research Institute, Munich (T.F.), Hospital Konstanz, Konstanz (F.H.), the Department of Cardiology and Electrophysiology, 
University Heart Center–Helios, and Leipzig Heart Institute, Leipzig (G.H.), University Heart Center Schleswig–Holstein, Campus Lü-
beck, Lübeck (K.-H.K.), Cardiology Practice Schön, Mühldorf (N.S.), and Cardiology Practice Taggeselle, Markkleeberg (J.T.) — all in 
Germany; the Institute of Cardiovascular Sciences, University of Birmingham, Birmingham (P.K.), the Cardiology Clinical Academic 
Group, Molecular and Clinical Sciences Research Institute, St. George’s University of London, London (A.J.C.), and the Department of 
Cardiovascular Sciences, University of Leicester, National Institute for Health Research Leicester Biomedical Research Centre, Glenfield 
Hospital, Leicester (G.A.N.) — all in the United Kingdom; the Department of Cardiology, Odense University Hospital, and Department 
of Clinical Research, University of Southern Denmark, Odense (A.B.); Isala Hospital and Diagram B.V., Zwolle (A.E.), the University of 
Groningen, University Medical Center Groningen, Groningen (I.C.G.), and the Department of Physiology, Cardiovascular Research 
Institute Maastricht (U.S.), and the Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Insti-
tute Maastricht (H.J.G.M.C.), Maastricht — all in the Netherlands; University Hospital Zurich, Zurich (L.M.H.), and the Division of 
Cardiology, Medical University Department, Kantonsspital Aarau, Aarau (L.M.H.) — both in Switzerland; University Hospital Antwerp 
and Antwerp University, Antwerp, Belgium (H.H.); the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.); 
the Hospital Clinic, University of Barcelona and Institut de Recerca Biomèdica, August Pi-Sunyer, Barcelona (L.M.), and Centro Inves-
tigación Biomedica en Red Cardiovascular, Madrid (L.M.); Department of Cardiology, Hospital Wojewódzka Stacja Pogotowia Ra-
tunkowego i Transportu Sanitarnego (WSRiTS) Meditrans, Warsaw, Poland (J.R.); the Department of Cardiology, Ospedale dell’Angelo, 
Venice, Italy (S.T.); and Heart Sector, Hygeia Hospitals Group, Athens (P.V.).
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on September 3, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 11
Early Rhythm-Control Ther apy
References
1. Marijon E, Le Heuzey J-Y, Connolly S, 
et al. Causes of death and influencing fac-
tors in patients with atrial fibrillation: a 
competing-risk analysis from the Ran-
domized Evaluation of Long-Term Antico-
agulant Therapy Study. Circulation 2013; 
128: 2192-201.
2. Willems S, Meyer C, de Bono J, et al. 
Cabins, castles, and constant hearts: 
rhythm control therapy in patients with 
atrial fibrillation. Eur Heart J 2019; 40: 
3793-3799c.
3. Kirchhof P, Radaideh G, Kim YH, et al. 
Global prospective safety analysis of riv a-
roxaban. J Am Coll Cardiol 2018; 72: 141-53.
4. Ruff CT, Giugliano RP, Braunwald E, 
et al. Comparison of the efficacy and 
safety of new oral anticoagulants with 
warfarin in patients with atrial fibrilla-
tion: a meta-analysis of randomised tri-
als. Lancet 2014; 383: 955-62.
5. Packer DL, Mark DB, Robb RA, et al. 
Effect of catheter ablation vs antiarrhyth-
mic drug therapy on mortality, stroke, 
bleeding, and cardiac arrest among pa-
tients with atrial fibrillation: the CABANA 
randomized clinical trial. JAMA 2019; 321: 
1261-74.
6. Hohnloser SH, Crijns HJGM, van 
Eickels M, et al. Effect of dronedarone on 
cardiovascular events in atrial fibrilla-
tion. N Engl J Med 2009; 360: 668-78.
7. Van Gelder IC, Hagens VE, Bosker 
HA, et al. A comparison of rate control and 
rhythm control in patients with recurrent 
persistent atrial fibrillation. N Engl J Med 
2002; 347: 1834-40.
8. Wyse DG, Waldo AL, DiMarco JP, et al. 
A comparison of rate control and rhythm 
control in patients with atrial fibrillation. 
N Engl J Med 2002; 347: 1825-33.
9. Benjamin EJ, Wolf PA, D’Agostino RB, 
Silbershatz H, Kannel WB, Levy D. Impact 
of atrial fibrillation on the risk of death: 
the Framingham Heart Study. Circulation 
1998; 98: 946-52.
10. Nattel S, Guasch E, Savelieva I, et al. 
Early management of atrial fibrillation to 
prevent cardiovascular complications. Eur 
Heart J 2014; 35: 1448-56.
11. Kirchhof P, Bax J, Blomstrom-Lund-
quist C, et al. Early and comprehensive 
management of atrial fibrillation: execu-
tive summary of the proceedings from the 
2nd AFNET-EHRA consensus conference 
‘research perspectives in AF.’ Eur Heart J 
2009; 30: 2969-77c.
12. Carlsson J, Miketic S, Windeler J, et al. 
Randomized trial of rate-control versus 
rhythm-control in persistent atrial fibril-
lation: the Strategies of Treatment of 
Atrial Fibrillation (STAF) study. J Am Coll 
Cardiol 2003; 41: 1690-6.
13. Roy D, Talajic M, Nattel S, et al. 
Rhythm control versus rate control for 
atrial fibrillation and heart failure. N Engl 
J Med 2008; 358: 2667-77.
14. Marrouche NF, Brachmann J, Andre-
sen D, et al. Catheter ablation for atrial 
fibrillation with heart failure. N Engl J 
Med 2018; 378: 417-27.
15. Tsadok MA, Jackevicius CA, Essebag 
V, et al. Rhythm versus rate control thera-
py and subsequent stroke or transient 
ischemic attack in patients with atrial fi-
brillation. Circulation 2012; 126: 2680-7.
16. Themistoclakis S, Corrado A, March-
linski FE, et al. The risk of thromboembo-
lism and need for oral anticoagulation 
after successful atrial fibrillation abla-
tion. J Am Coll Cardiol 2010; 55: 735-43.
17. Bunch TJ, Crandall BG, Weiss JP, et al. 
Patients treated with catheter ablation for 
atrial fibrillation have long-term rates of 
death, stroke, and dementia similar to pa-
tients without atrial fibrillation. J Cardio-
vasc Electrophysiol 2011; 22: 839-45.
18. Noseworthy PA, Gersh BJ, Kent DM, et 
al. Atrial fibrillation ablation in practice: 
assessing CABANA generalizability. Eur 
Heart J 2019; 40: 1257-64.
19. Kirchhof P, Breithardt G, Camm AJ, et 
al. Improving outcomes in patients with 
atrial fibrillation: rationale and design of 
the Early treatment of Atrial fibrillation 
for Stroke prevention Trial. Am Heart J 
2013; 166: 442-8.
20. Camm AJ, Kirchhof P, Lip GYH, et al. 
Guidelines for the management of atrial 
fibrillation: the Task Force for the Man-
agement of Atrial Fibrillation of the Euro-
pean Society of Cardiology (ESC). Euro-
pace 2010; 12: 1360-420.
21. January CT, Wann LS, Alpert JS, et al. 
2014 AHA/ACC/HRS guideline for the 
management of patients with atrial fibril-
lation: a report of the American College of 
Cardiology/American Heart Association 
Task Force on Practice Guidelines and the 
Heart Rhythm Society. J Am Coll Cardiol 
2014; 64(21): e1-e76.
22. Kirchhof P, Benussi S, Kotecha D, et 
al. 2016 ESC guidelines for the manage-
ment of atrial fibrillation developed in 
collaboration with EACTS. Eur Heart J 
2016; 37: 2893-962.
23. Committee for Medicinal Products for 
Human Use (CHMP). Reflection paper on 
methodological issues in confirmatory clini-
cal trials planned with an adaptive design. 
London: European Medicines Agency, Octo-
ber 18, 2007 (https://www . ema . europa . eu/ 
 en/ documents/ scientific - guideline/ 
 reflection - paper - methodological - issues 
- confirmatory - clinical - trials - planned 
- adaptive - design_en . pdf).
24. Tsiatis AA, Rosner GL, Mehta CR. Ex-
act confidence intervals following a group 
sequential test. Biometrics 1984; 40: 797-
803.
25. Glorioso TJ, Grunwald GK, Ho PM, 
Maddox TM. Reference effect measures 
for quantifying, comparing and visualiz-
ing variation from random and fixed ef-
fects in non-normal multilevel models, 
with applications to site variation in med-
ical procedure use and outcomes. BMC 
Med Res Methodol 2018; 18: 74.
26. Cosedis Nielsen J, Johannessen A, 
Raatikainen P, et al. Radiofrequency abla-
tion as initial therapy in paroxysmal atrial 
fibrillation. N Engl J Med 2012; 367: 1587-
95.
27. Duytschaever M, Demolder A, Phlips 
T, et al. PulmOnary vein isolation With vs. 
without continued antiarrhythmic Drug 
trEatment in subjects with Recurrent Atri-
al Fibrillation (POWDER AF): results from 
a multicentre randomized trial. Eur Heart 
J 2018; 39: 1429-37.
28. Darkner S, Chen X, Hansen J, et al. 
Recurrence of arrhythmia following short-
term oral AMIOdarone after CATheter ab-
lation for atrial fibrillation: a double-blind, 
randomized, placebo-controlled study 
(AMIO-CAT trial). Eur Heart J 2014; 35: 
3356-64.
29. Connolly SJ, Crijns HJGM, Torp-Ped-
ersen C, et al. Analysis of stroke in 
ATHENA: a placebo-controlled, double-
blind, parallel-arm trial to assess the ef-
ficacy of dronedarone 400 mg BID for the 
prevention of cardiovascular hospitaliza-
tion or death from any cause in patients 
with atrial fibrillation/atrial f lutter. Cir-
culation 2009; 120: 1174-80.
30. Connolly SJ, Camm AJ, Halperin JL, et 
al. Dronedarone in high-risk permanent 
atrial fibrillation. N Engl J Med 2011; 365: 
2268-76.
Copyright © 2020 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on September 3, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
